Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Bullboard Posts
Post by lhornson Jul 28, 2008 4:21pm
338 Views
Post# 15336924

stock price

stock priceI won't be surprised to see the price of Isotechnika drift lower over the next 6-8 weeks or so. There is nothing to drive it upwards at present. If Isotechnika's management can swing a deal with another large pharma the price will take off again. If however there are no companies willing to take a chance on Voclosporin then as we all know the company has huge problems with funding the ongoing trials that are needed for future development of the drug and the outlook will not be rosy. 
There is not much that can be done except to sit tight and hope that the science behind the drug will stand up to reviews by companies that truly want to develop a Calcineurin Inhibitor in transplantation and or in psoriasis. I would also advise against supporting any offer to purchase the company outright if the offer price is below 1.50 -2$ dollar range. If a big pharma is truly interested in Voclosporin then they will be willing to pay at least what Roche was going to offer Isotechnika which for biotech' companies with a Phase3  drug close to market is at least 3-4$/share. Any bid by a large pharma means that they believe that Isotechnika's voclosporin has the potential that management states. If they didn't believe this why waste 60-100$ million dollars on a lowball bid for something you don't really want.So again the bottom line is hang tough and don't get too concerned watching daily ISA stock quotes. In the short term it will only get you depressed.

Naomi2
Bullboard Posts